Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Radiation Oncology›Clinical Question·Updated Jul 2, 2026·v1

Role of SBRT in Oligometastatic NSCLC [DeepSeek Flash GROUNDED]

Evidence-based overview of Role of stereotactic body radiation therapy (SBRT) in metastatic lung cancer.

Moderate Evidence22 references·1,361 words·6 min read·v1
Radiation Oncologyrole of stereotactic body radiation therapy (sbrt) in metastatic lung cancer
SBRT (stereotactic body radiation therapy) has emerged as a local ablative strategy for oligometastatic NSCLC, primarily in patients with ≤5 metastases. In EGFR-mutant disease stable on TKI, adding SBRT significantly prolongs PFS and OS. For immunotherapy-exposed patients, SBRT combinations show numerically improved ORR. Patient selection is critical: avoid central lung lesions and polymetastatic disease. Evidence is limited by absence of phase III data.

Deep Dive — Evidence Details

References

  1. [1]

    Cho BC, Lim SM, Lee SH et al.. “MORPHEUS-Lung: biomarkers and clinical response to atezolizumab + bevacizumab + stereotactic body radiotherapy in patients with metastatic non-small cell lung cancer.” Lung cancer (Amsterdam, Netherlands) (2026). PMID: 42103553 ↗

    L2RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
  2. [2]

    Ghiringhelli F, Lawrence YR, Felip E et al.. “Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor and chemotherapy: results from the randomized, phase Ib/II MORPHEUS-Lung study.” Journal for immunotherapy of cancer (2025). PMID: 40759444 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, On the Horizon
  3. [3]

    Peng P, Gong J, Zhang Y et al.. “EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV Non-small cell lung cancer (NSCLC): A prospective, multicenter, randomized, controlled phase II study.” Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2023). PMID: 37105304 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
  4. [4]

    Bestvina CM, Pointer KB, Karrison T et al.. “A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study.” Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer (2021). PMID: 34500113 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
  5. [5]

    Zelefsky MJ, Yamada Y, Greco C et al.. “Phase 3 Multi-Center, Prospective, Randomized Trial Comparing Single-Dose 24 Gy Radiation Therapy to a 3-Fraction SBRT Regimen in the Treatment of Oligometastatic Cancer.” International journal of radiation oncology, biology, physics (2021). PMID: 33422612 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
  6. [6]

    Welsh J, Menon H, Chen D et al.. “Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial.” Journal for immunotherapy of cancer (2020). PMID: 33051340 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
  7. [7]

    Chen D, Menon H, Verma V et al.. “Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: retrospective analysis of two single-institution prospective trials.” Journal for immunotherapy of cancer (2020). PMID: 31996395 ↗

    L3RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
  8. [8]

    Guckenberger M, Opitz I, Dellaporta T et al.. “Multimodality treatment in synchronous oligometastatic NSCLC: Analysis of the ETOP CHESS trial.” Lung cancer (Amsterdam, Netherlands) (2025). PMID: 40311307 ↗

    L4TRIAL_NONRANDOMCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats, On the Horizon
  9. [9]

    Keane FK, Yeap BY, Khandekar MJ et al.. “Phase 2 Trial of Consolidative Stereotactic Body Radiation Therapy in Patients With Metastatic Oncogene-driven Non-small Cell Lung Carcinoma Treated With Tyrosine Kinase Inhibitors.” International journal of radiation oncology, biology, physics (2024). PMID: 39577475 ↗

    L4TRIAL_NONRANDOMCited in: Bottom Line, Current Evidence and Standard, On the Horizon
  10. [10]

    Franceschini D, Franzese C, Comito T et al.. “Definitive results of a prospective non-randomized phase 2 study on stereotactic body radiation therapy (sbrt) for medically inoperable lung and liver oligometastases from breast cancer.” Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2024). PMID: 38522597 ↗

    L4TRIAL_NONRANDOMCited in: Bottom Line, Current Evidence and Standard, Applicability and Caveats
  11. [11]

    Bassetti MF, Morris BA, Sethakorn N et al.. “Combining Dual Checkpoint Immunotherapy with Ablative Radiation to All Sites of Oligometastatic Non-Small Cell Lung Cancer: Toxicity and Efficacy Results of a Phase 1b Trial.” International journal of radiation oncology, biology, physics (2023). PMID: 38072321 ↗

    L4TRIAL_NONRANDOMCited in: Current Evidence and Standard, Applicability and Caveats
  12. [12]

    Zhou X, Zhou L, Yao Z et al.. “Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1+ Non-Small Cell Lung Cancer Patients.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 37581611 ↗

    L4TRIAL_NONRANDOMCited in: Current Evidence and Standard
  13. [13]

    Kim KH, Yoon S, Ahn HK et al.. “A Multicenter Two-arm, Phase II Trial Assessing the Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer (ABLATE, KCSG-LU21-11).” Clinical lung cancer (2022). PMID: 36002368 ↗

    L5TRIAL_NONRANDOMCited in: Applicability and Caveats
  14. [14]

    Navarria P, Baldaccini D, Clerici E et al.. “Stereotactic Body Radiation Therapy for Lung Metastases From Sarcoma in Oligometastatic Patients: A Phase 2 Study.” International journal of radiation oncology, biology, physics (2022). PMID: 35987453 ↗

    L4TRIAL_NONRANDOMCited in: Applicability and Caveats
  15. [15]

    Van Limbergen EJ, Hoeben A, Lieverse RIY et al.. “Toxicity of L19-Interleukin 2 Combined with Stereotactic Body Radiation Therapy: A Phase 1 Study.” International journal of radiation oncology, biology, physics (2020). PMID: 33285270 ↗

    L4TRIAL_NONRANDOMCited in: Applicability and Caveats
  16. [16]

    Radwan N, Phillips R, Ross A et al.. “A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).” BMC cancer (2017). PMID: 28662647 ↗

    L5RCTCited in: Applicability and Caveats
  17. [17]

    Tsao MN, Ven LI', Cheung P et al.. “Stereotactic Body Radiation Therapy for Extracranial Oligometastatic Non-small-cell Lung Cancer: A Systematic Review.” Clinical lung cancer (2019). PMID: 31959533 ↗

    L2SR_OBSCited in: Applicability and Caveats
  18. [18]

    Tsai CJ, Yang JT, Shaverdian N et al.. “Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study.” Lancet (London, England) (2023). PMID: 38104577 ↗

    L1RCTCited in: On the Horizon
  19. [19]

    Zhang R, Chen M, Yin N et al.. “Low-dose radiation and stereotactic body radiotherapy with PD-1 inhibitor sintilimab and chemotherapy for first-line treatment of locally advanced or metastatic squamous lung cancer: protocol for a randomised phase II trial (IHC002 study).” BMJ open (2025). PMID: 40887121 ↗

    L5TRIAL_NONRANDOMCited in: On the Horizon
  20. [20]

    Filippi AR, Rulli E, Signorelli D et al.. “Rationale and Design of the AUSTRAL trial: An Open-Label, Multicenter, Phase II Study Evaluating Radiotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Stage III NSCLC Patients With Thoracic Relapses and/or Oligometastases After the PACIFIC Regimen.” Clinical lung cancer (2025). PMID: 40781023 ↗

    L5TRIAL_NONRANDOMCited in: On the Horizon
  21. [21]

    Huang J, Theelen WSME, Belcaid Z et al.. “Combination of pembrolizumab and radiotherapy induces systemic antitumor immune responses in immunologically cold non-small cell lung cancer.” Nature cancer (2025). PMID: 40696153 ↗

    L4TRIAL_NONRANDOMCited in: On the Horizon
  22. [22]

    Chuong MD, Mittauer KE, Bassetti MF et al.. “Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy in One Fraction (SMART ONE): A Multicenter, Single-Arm, Phase 2 Trial.” International journal of radiation oncology, biology, physics (2025). PMID: 40158734 ↗

    L4TRIAL_NONRANDOMCited in: On the Horizon

Revision History

All updates applied to this page

Loading revisions…